Journal Scans
Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab
PET Predicts Outcomes of Rituximab-Based Treatment for DLBCL
V Safar, J Dupuis, E Itti, F Jardin, C Fruchart, S Bardet, P Vera, C Copie-Bergman, A Rahmouni, H Tilly, M Meignan, C Haioun
20111112
2011 Dec 12
J Clin Oncol
Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab
J Clin Oncol. 2011 Dec 12;[Epub Ahead of Print], V Safar, J Dupuis, E Itti, F Jardin, C Fruchart, S Bardet, P Vera, C Copie-Bergman, A Rahmouni, H Tilly, M Meignan, C Haioun
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Response to treatment and treatment outcomes are heterogeneous in patients with diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin's lymphoma. Prognostic indicators are needed to help identify likelihood of response to treatment. This retrospective study evaluated the value of interim positron emission tomography (PET) imaging as a prognostic tool for patients with DLBCL treated with rituximab and anthracycline-based chemotherapy.Data were obtained from three institutions in France that...
